TRCT
GANX icon

Tower Research Capital (TRC)’s Gain Therapeutics GANX Stock Holding History

Tower Research Capital (TRC)’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.9K Buy
8,321
+2,815
+51% +$5.19K ﹤0.01% 3689
2026
Q1 		$10.7K Sell
5,506
-1,353
-20% -$2.94K ﹤0.01% 3877
2025
Q4 		$22.1K Buy
6,859
+4,795
+232% +$12.8K ﹤0.01% 3021
2025
Q3 		$3.65K Buy
2,064
+1,119
+118% +$1.89K ﹤0.01% 4469
2025
Q2 		$1.7K Sell
945
-1,487
-61% -$2.75K ﹤0.01% 4760
2025
Q1 		$4.64K Buy
+2,432
New +$5.39K ﹤0.01% 4222
2024
Q4 		– Sell
-4,842
Closed -$8.62K – 5792
2024
Q3 		$8.62K Buy
4,842
+3,113
+180% +$3.91K ﹤0.01% 3948
2024
Q2 		$2.21K Sell
1,729
-2,903
-63% -$7.54K ﹤0.01% 5040
2024
Q1 		$17.5K Sell
4,632
-260
-5% -$1.08K ﹤0.01% 3122
2023
Q4 		$16K Buy
4,892
+2,022
+70% +$5.62K ﹤0.01% 3798
2023
Q3 		$9.41K Sell
2,870
-1,477
-34% -$5.6K ﹤0.01% 4221
2023
Q2 		$19.5K Sell
4,347
-2,497
-36% -$12.2K ﹤0.01% 3405
2023
Q1 		$33K Sell
6,844
-308
-4% -$1.26K ﹤0.01% 2893
2022
Q4 		$23K Buy
7,152
+1,891
+36% +$5.91K ﹤0.01% 2992
2022
Q3 		$17K Buy
5,261
+4,545
+635% +$17.1K ﹤0.01% 4064
2022
Q2 		$3K Buy
716
+123
+21% +$424 ﹤0.01% 5374
2022
Q1 		$2K Sell
593
-577
-49% -$2.41K ﹤0.01% 5548
2021
Q4 		$7K Buy
1,170
+615
+111% +$4.24K ﹤0.01% 4909
2021
Q3 		$4K Buy
555
+483
+671% +$4.04K ﹤0.01% 4970
2021
Q2 		$0 Buy
+72
New +$812 ﹤0.01% 5595

Other funds holding GANX

Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
PCM
Potomac Capital Management New York $147M AUM
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
DCM
DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Tower Research Capital (TRC)'s GANX Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Gain Therapeutics (GANX) stake by 51% in Q2 2026, buying an estimated $5.19K and bringing the position to 8,321 shares worth $16.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3689.

Tower Research Capital (TRC) first reported a position in GANX in Q2 2021 and has held it in 20 quarters since. The position peaked at $33K in Q1 2023. 50 funds tracked by Wall St. Rank hold GANX as of Q2 2026.

  • Tower Research Capital (TRC) held 8,321 shares of Gain Therapeutics worth $16.9K as of Q2 2026.
  • Tower Research Capital (TRC) bought 2,815 Gain Therapeutics shares in Q2 2026, an estimated $5.19K.
  • Gain Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3689 holding.
  • Tower Research Capital (TRC) first reported a position in Gain Therapeutics in Q2 2021 and has held it in 20 quarters since.
  • Tower Research Capital (TRC)'s Gain Therapeutics position peaked at $33K in Q1 2023.
  • 50 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.